Inclusion Criteria:

• Age 0-90 years

• Documentation of confirmed diagnosis of PCD.  For the pilot, diagnosis by either hallmark ciliary ultrastructure abnormality confirmed at a PCD expert site OR two known disease-causing mutations in a known PCD gene.  For subsequent enrollment individuals diagnosed by low nNO testing (<77nl/min) on two separate occasions at least two months apart plus a compatible clinical phenotype will also be included

• Written informed consent, and assent for minors as applicable

• Followed as a patient at a PCD Foundation Clinical and Research Network center in North America

Exclusion Criteria:

• Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by the IRB) OR inability of parent/guardian to understand the requirements of the study

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/05/2025. Questions regarding updates should be directed to the study team contact.